市場調査レポート

商品コード

1566127

ファーマコゲノミクスの市場規模、シェア、成長分析、製品・サービス別、技術別、疾患領域別、用途別、地域別 - 産業予測、2024年～2031年

Pharmacogenomics Market Size, Share, Growth Analysis, By Product & Service, By Technology, By Disease Area, By Application, By Region - Industry Forecast 2024-2031

出版日: 2024年10月03日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

ファーマコゲノミクス市場規模は2022年に61億5,000万米ドルと評価され、2023年の66億7,000万米ドルから2031年には127億8,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは8.47％で成長する見通しです。

世界の市場情勢は、ゲノム研究の躍進、個別化医療の台頭、プレシジョン・ヘルスケアの進展などの影響を受け、力強い成長と変貌を遂げています。個別化された治療オプションに関する意識の高まりは、臨床プロトコルへのゲノム検査の統合の増加と相まって、特に慢性疾患が蔓延するにつれて市場拡大を後押ししています。さらに、標的治療の出現と並んで、ゲノムデータと電子カルテの融合が市場のダイナミクスを著しく高めています。製薬企業、研究機関、規制当局の協力体制も、薬理ゲノム研究を大きく進展させています。とはいえ、遺伝子検査に関連する高額な費用、制限的な償還政策、広範な研究開発努力の差し迫った必要性など、市場は課題に直面しています。これらの障壁に対処し、臨床現場でファーマコゲノミクスを最大限に活用することが、市場の継続的な成功にとって極めて重要です。特に、米国のファーマコゲノミクス分野は、今後の予測年においても持続的なCAGRを維持すると予想されており、この革新的な分野における将来の発展と投資機会への強い可能性を示しています。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Illumina, Inc.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
QIAGEN
Danaher Corporation
Laboratory Corporation of America Holdings
Eurofins Scientific
Charles River Laboratories
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
Becton, Dickinson and Company
Revvity
IQVIA, Inc.
Mesa Labs, Inc.
Medpace, Inc.
MGI Tech Co., Ltd.
PacBio
Takara Bio Inc.
New England Biolabs
BGI
Novogene Co., Ltd.
Sophia Genetics
Fios Genomics
Personalis, Inc.
NeoGenomics Laboratories
BioAI Health Inc.
Macrogen, Inc.

Product Code: SQMIG35G2248

Pharmacogenomics Market size was valued at USD 6.15 billion in 2022 and is poised to grow from USD 6.67 billion in 2023 to USD 12.78 billion by 2031, growing at a CAGR of 8.47% in the forecast period (2024-2031).

The global pharmacogenomics market is witnessing robust growth and a transformative landscape, largely influenced by breakthroughs in genomic research, the rise of personalized medicine, and the advancement of precision healthcare. A surge in awareness regarding personalized treatment options, coupled with an increasing integration of genomic testing into clinical protocols, is propelling market expansion, especially as chronic diseases become more prevalent. Furthermore, the amalgamation of genomic data with electronic health records, alongside the emergence of targeted therapies, is significantly enhancing market dynamics. Collaborative efforts among pharmaceutical firms, research institutions, and regulatory agencies are also driving considerable progress in pharmacogenomic research. Nonetheless, the market faces challenges, including the high costs associated with genetic testing, restrictive reimbursement policies, and a pressing necessity for extensive R&D efforts. Addressing these barriers and maximally utilizing pharmacogenomics in clinical settings will be crucial for the ongoing success of the market. In particular, the U.S. pharmacogenomics sector is expected to maintain a sustainable compound annual growth rate (CAGR) in the upcoming forecast year, indicating strong potential for future development and investment opportunities within this innovative field.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pharmacogenomics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pharmacogenomics Market Segmental Analysis

Global Pharmacogenomics Market is segmented by Product & Service, Technology, Disease Area, Application, End User and region. Based on Product & service, the market is segmented into Kits & Reagents (Sequencing Kits and Reagents, PCR Kits and Reagents, Microarray Kits and Reagents, Other Kits and Reagents), Service. Based on Technology, the market is segmented into Sequencing, PCR, Microarray, and Other Technologies. Based on Disease Area, the market is segmented into Cancer, Cardiovascular, Neurological Diseases, Other Disease Areas. Based on Application, the market is segmented into Personalized Medicine, Clinical Research, Drug discovery & Preclinical Development. Based on End User, the market is segmented into Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Pharmacogenomics Market

The rising demand for personalized medicine significantly propels the global pharmacogenomics market, as healthcare stakeholders increasingly recognize the importance of tailoring drug therapies to individual genetic profiles. By leveraging pharmacogenomic insights, clinicians can optimize medication selection and dosages, enhancing efficacy and minimizing adverse effects, thereby leading to safer treatment regimens. This shift towards precision medicine not only improves patient health outcomes but also fosters healthcare efficiency and cost-effectiveness. As more healthcare systems integrate pharmacogenomic testing into routine practices, the market is poised for substantial growth, reflecting a broader trend towards individualized healthcare solutions that cater to each patient's unique genetic makeup.

Restraints in the Pharmacogenomics Market

The global pharmacogenomics market faces significant restraint due to the high costs associated with genetic testing and genomic analysis. These advanced tests necessitate sophisticated laboratory infrastructure and specialized expertise, resulting in expensive procedures that can limit accessibility for patients, particularly in developing regions where healthcare resources are constrained. Moreover, the complex nature of interpreting and integrating genetic data into clinical workflows demands additional specialized training and resources. These financial and technical challenges create substantial barriers to the widespread adoption of pharmacogenomic services, ultimately affecting the market's growth potential and the realization of personalized medicine benefits across diverse populations.

Market Trends of the Pharmacogenomics Market

A prominent trend in the global pharmacogenomics market is the widespread integration of personalized medicine, which tailors drug therapies to align with an individual's unique genetic profile. This paradigm shift, fueled by advancements in genomic research and increased accessibility to genetic testing technologies, empowers healthcare providers to optimize treatment efficacy and mitigate adverse drug reactions. As the healthcare industry increasingly recognizes the importance of genetic insights in medication management, the implementation of pharmacogenomics in clinical settings is anticipated to accelerate, heralding a new era of targeted therapies. This evolution not only enhances patient outcomes but also signifies robust growth potential for the pharmacogenomics market in the coming years.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Technology Analysis
Value Chain Analysis
Supply Chain Analysis
Regulatory Landscape
Pricing Analysis
Patent Analysis
Customer & Buying Criteria Analysis

Pharmacogenomics Market, By Product & Service

Market Overview
Kits & Reagents
- Sequencing Kits & Reagents
- PCR Kits & Reagents
- Microarray Kits & Reagents
- Other Kits & Reagents
Services

Pharmacogenomics Market, By Technology

Market Overview
Sequencing
PCR
Microarray
Other Technologies

Pharmacogenomics Market, By Application

Market Overview
Personalized Medicine
Clinical Research
Drug Discovery & Preclinical Development

Pharmacogenomics Market, By Disease Area

Market Overview
Cancer
Cardiovascular Disease
Neurological Disorders
Other Disease Areas

Pharmacogenomics Market, By End User

Market Overview
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Contract Research Organizations

Pharmacogenomics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Illumina, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Laboratory Corporation of America Holdings
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Revvity
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IQVIA, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mesa Labs, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medpace, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MGI Tech Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PacBio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takara Bio Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
New England Biolabs
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BGI
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novogene Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sophia Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fios Genomics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Personalis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeoGenomics Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioAI Health Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Macrogen, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

ファーマコゲノミクスの市場規模、シェア、成長分析、製品・サービス別、技術別、疾患領域別、用途別、地域別 - 産業予測、2024年～2031年

Pharmacogenomics Market Size, Share, Growth Analysis, By Product & Service, By Technology, By Disease Area, By Application, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

ファーマコゲノミクス市場：製品・サービス別

ファーマコゲノミクス市場：技術別

ファーマコゲノミクス市場：用途別

ファーマコゲノミクス市場：疾患領域別

ファーマコゲノミクス市場：エンドユーザー別

ファーマコゲノミクス市場規模：地域別